Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026)
Planet 13 Holdings' (PLNH) quarterly Net Income towards Common Stockholders came in at -$8.1 million in Q1 2026, down 295.46% year-on-year from $4.1 million in Q1 2025, and down 215.53% on a QoQ basis from $7.0 million in Q4 2025.
Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$8.1 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 295.46% year-over-year to -$8.1 million in Q1 2026; TTM through Mar 2026 was -$58.3 million, a 32.69% decrease from a year earlier, with the FY2025 full-year figure at -$52.3 million, down 9.42% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$8.1 million, down from $7.0 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for PLNH reached as high as $7.0 million in Q4 2025 and fell as low as -$46.3 million in Q3 2023.
- Historically, Net Income towards Common Stockholders has averaged -$14.2 million across 5 years, with a median of -$8.1 million in 2024.
- Across the five-year window, Net Income towards Common Stockholders tumbled 2131.73% in 2022 and surged 126.5% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$42.1 million in 2022, then jumped by 66.13% to -$14.3 million in 2023, then slumped by 85.43% to -$26.4 million in 2024, then jumped by 126.5% to $7.0 million in 2025, then plunged by 215.53% to -$8.1 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$8.1 million in Q1 2026, $7.0 million in Q4 2025, and -$44.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Planet 13 Holdings | 39.42 Mn | 23.16 Mn | 9.41 Mn | -8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.10 Mn |
| Dec 31, 2025 | 7.01 Mn |
| Sep 30, 2025 | -43.96 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Dec 31, 2024 | -26.44 Mn |
| Sep 30, 2024 | -7.41 Mn |
| Jun 30, 2024 | -8.07 Mn |
| Mar 31, 2024 | -5.87 Mn |
| Dec 31, 2023 | -14.26 Mn |
| Sep 30, 2023 | -46.25 Mn |
| Jun 30, 2023 | -4.62 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -42.09 Mn |
| Sep 30, 2022 | -6.32 Mn |
| Jun 30, 2022 | -7.07 Mn |
| Mar 31, 2022 | -4.06 Mn |
| Dec 31, 2021 | -12.46 Mn |
| Sep 30, 2021 | 4.05 Mn |
| Jun 30, 2021 | 347,962.00 |